Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment

19 Dec 2024

Abstract excerpt

Abstract Background Diffuse IDH mutant low-grade gliomas (IDHmt LGG) (World Health Organization grade 2) typically affect young adults. The outcome is variable, with survival ranging from 5 to over 20 years. The timing and choice of initial treatments after surgery remain controversial. In particular, radiotherapy is associated with early and late cognitive toxicity. Over 90% of IDHmt LGG exhibit some degree of...

Source

Identifiers

PMID: 40041202
DOI: 10.1093/noajnl/vdae224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentPMID 40041202Read ↗

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Semantic proximity Read ↗

Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort studySemantic proximity Read ↗

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastomaSemantic proximity Read ↗

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapySemantic proximity Read ↗

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomasSemantic proximity Read ↗

<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomasSemantic proximity Read ↗

Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population.Semantic proximity Read ↗

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Semantic proximity Read ↗

Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.Semantic proximity Read ↗

No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patientsSemantic proximity Read ↗

Combined <i>MGMT</i> Expression and MMR Deficiency Underlie Poor Outcomes of Temozolomide in <i>IDH</i> -Wildtype Grade 2 GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.